Co-D Therapeutics Granted Orphan Designation for Triolimus for the Treatment of Angiosarcoma

Co-D Therapeutics, Inc., a pre-clinical stage pharmaceutical company developing agents for the treatment of cancer, announced that the U.S. Food and Drug Administration (FDA) has granted Co-D’s request for orphan drug designation of Triolimus for the treatment of the highly lethal malignancy, angiosarcoma. “We are pleased that Triolimus has been designated an orphan drug for the treatment of angiosarcoma,” commented Dr. Kevin Kozak, co-founder and Chief Medical Officer of Co-D Therapeutics. “With few effective options, new agents for angiosarcoma treatment are urgently required. The orphan designation reflects both the FDA’s and Co-D’s commitment to addressing the unmet clinical needs of patients with rare diseases like angiosarcoma.”